Beruflich Dokumente
Kultur Dokumente
Lipid basics
Lipids are fatty substances that are required for maintenance of normal bodily function.
Cholesterol and triglycerides are the major lipids that circulate in blood plasma and are
transported in globules known as lipoproteins. Cholesterol is an important component of cell
membranes and is required for the synthesis of steroid hormones and bile acids. As the daily
requirement for cholesterol cannot be met from dietary intake, the majority (80%) is derived
from biosynthesis in the liver. Triglycerides are the storage form of fatty acids, derived from the
diet or synthesised in the liver, which are an important source of energy and fatty acids required
for formation of phospholipids, an essential component of cell membranes. Both the liver and the
gut package cholesterol, triglycerides and fat-soluble vitamins into lipoproteins for delivery to
other tissues.
Lipoprotein fractions
All lipoproteins have a common basic structure (figure 1) but they vary greatly in their size,
density and composition (figure 2 and table 1).
Figure 2. The lipoprotein particle family
Table 1. The composition of the various lipoproteins and their transport pathways
Lipid fractions are mixtures of lipoproteins of similar size and density which can be separated by
the ultracentrifuge and are named accordingly as:
high density lipoproteins (HDL)
low density lipoproteins (LDL)
very low density lipoproteins (VLDL).
As VLDL are metabolised into LDL (see below), short-lived intermediate density lipoproteins
are also seen (IDL).
Chylomicrons, which appear after meals, are the largest and lowest density lipoproteins and
rapidly float to the top of stored plasma without ultracentrifugation. Chylomicrons are rapidly
metabolised into smaller VLDL sized particles (chylomicron remnants).
Apolipoproteins
In addition to their lipid components, lipoproteins contain specific protein components known as
apolipoproteins which provide a structural framework and have a number of other important
functions, including binding to receptors and activation of lipid transporters and metabolising
enzymes. More detail on specific apolipoproteins can be found in the drop down box.
Figure 3 shows the intestinal (exogenous) pathway. Cholesterol and triglycerides derived from
dietary lipids are absorbed in the gut and incorporated into chlyomicrons, regulated by the
Niemann-Pick C1-Like 1 (NPC1L1) gene and microsomal triglyceride transfer protein (MTP). These
very large, triglyceride-rich lipoproteins are secreted into the lymph and bypass the liver,
entering the plasma post-prandially via the thoracic duct. Chylomicrons deliver the fat to adipose
tissue via lipoprotein lipase (LPL) which allows it to be taken up rapidly in the form of fatty
acids. Once small enough the resulting chylomicron remnant is removed from plasma by the liver
via apoE (see drop down box) binding to the remnant receptor (LRP) or to the LDL receptor
(LDLR). Left over surface material and exchangeable apolipoproteins (AI AII AIV, CI CII CIII and E)
may enter the HDL pool as nascent HDL. Between meals (post-absorptive phase), as insulin
levels fall, fatty acids are released from adipose tissue by lipolysis and enter the circulation
bound to albumin.
Fatty acids, arriving at the liver bound to albumin or newly-synthesised (de novo lipogenesis), are
re-esterified to form triglyceride and together with cholesterol are loaded onto apoB to form
VLDL. These large triglyceride rich lipoproteins enter the plasma between meals and deliver the
fat to adipose tissue and muscle via lipoprotein lipase (LPL) which allows it to be taken up in the
form of fatty acids (see figure 4). Once small enough, the resulting IDL is either taken up directly
by the liver (cf. Chylomicron remnant) or converted to LDL by hepatic lipase (HL). That LDL is
then taken up by peripheral tissues via the LDLR to meet local cholesterol needs. Any left over
LDL particles are finally removed by the liver via the LDLR.
HDL inhibits the development of atheroma and coronary artery disease by transporting excess
tissue cholesterol to the liver, where it is converted into bile acids and excreted (figure 5) Lower
levels of HDL have been correlated with an increased risk of atherosclerosis, the primary cause of
cardiovascular disease. The principal HDL pathway, termed reverse cholesterol transport (RCT) is
a major component of lipid homeostasis. Cholesteryl ester transfer protein (CETP) is responsible
for the exchange of cholesteryl esters from HDL to more atherogenic cholesterol fractions
including LDL and VLDL. Individuals lacking in the gene encoding CETP have been identified as
having lower cardiovascular risk and the enzyme has become a pharmaceutical target (see
module 4 for more on CETP inhibitors as a drug class).
Nascent HDL, in the form of flattened discs, is generated from LPL- mediated lipolysis of
triglyceride rich lipoproteins (TRLs,) including (VLDL and cChylomicrons), or triglyceride rich
lipoproteins (TRLs) or secreted directly from the gut or liver, and enters plasma and where it
picks up additional exchangeable apolipoproteins.
Free cholesterol is removed from deposits in peripheral tissues via ATP-binding cassette A1
(ABCA1) activated by apoA1, rapidly esterified by the action of lecithin cholesterol acyl
transferase (LCAT) and funnelled into the core of the new HDL particle converting it to the
mature spherical form. Core lipid exchanges between HDL and TRLs occur in the circulation,
catalysed by CETP. This allows cholesterol to be offloaded from HDL into VLDL and LDL which are
destined for hepatic uptake, permitting further cholesterol uptake from tissues. Finally the
cholesterol-enriched HDL particle returns cholesterol to the liver for biliary excretion. The
cholesterol-depleted HDL particles can then return to the circulation to undertake more reverse
cholesterol transport.
Cholesterol homeostasis
The rate of cholesterol formation by the liver and absorption by the small intestine is highly
responsive to the cellular level of cholesterol. This feed back regulation is controlled primarily by
changes in the amount and activity of 3-hydroxy-3 methylglutaryl CoA reductase (HMGCoA
reductase). This enzyme catalyses formation of mevalonate, the committed step in cholesterol
biosynthesis. (For more detail on this process of cholesterol homeostasis, see dropdown box).
Figure 6. Cholesterol homeostasis
ApolipoproteinsHide details
Apolipoproteins B100 and B48 are two proteins produced from the same gene, due to editing of mRNA in the gut.
ApoB48 is exclusive to chylomicrons and chylomicron remnants. ApoB48 contains 48% of the sequence of apoB100, and
lacks the ligand binding domain recognised by the LDL-receptor (LDLR), so that hepatic removal chylomicron remnants is
dependent on ApoE.
ApoE is required for hepatic clearance of chylomicron and VLDL remnants (IDL) via the LDL receptor (LDLR) and LDLR-
like receptor protein 1 (LRP1). ApoE has 3 common Isoforms (E3, E4, E2). Of the 6 common genotypes, E3/E3 is the most
prevalent. E2 exhibits defective binding to LDLR (<2% of E3) predisposing to remnant (Type III) hyperlipidaemia (familial
dysbetalipoproteinaemia), which is usually associated with the E2/E2 genotype.
ApoB100 remains with VLDL as it undergoes lipolysis to IDL and LDL whereas exchangeable apolipoproteins (e.g. ApoE
and apoC-II) can transfer between particles. As each LDL particle contains one molecule of apolipoprotein B100,
apolipoprotein B concentration is a measure of LDL particle numbers.
Lipoprotein(a) is a highly atherogenic and thrombogenic lipoprotein formed by covalent bonding between the
apolipoprotein B of the LDL particle and apolipoprotein(a), an apparently vestigial plasminogen-like protein which
increases its retention in the artery wall (see figure 8). Genetic variants of apo(a) which are smaller in size generate
greater numbers of liporotein(a) particles, concentrations of which show 100-fold variation between individuals.
References
1. Yusuf S, Hawken S, Ounpuu S, on behalf of the INTERHEART Study Investigators. Effect of
potentially modifiable risk factors associated with myocardial infarction in 52 countries (the
INTERHEART study): case-control study. Lancet 2004;364:93752.
http://dx.doi.org/10.1016/S0140-6736(04)17018-9
2. Durrington PN. Hyperlipidaemia: diagnosis and management (3rd Edition). Hodder Arnold
2007. http://dx.doi.org/10.1201/b13464
3. Garg A (ed). Dyslipidaemias: pathophysiology, evaluation and management. Humana Press
2015. http://dx.doi.org/10.1007/978-1-60761-424-1
4. Tabas I, Williams KJ, Born J. Subendothelial lipoprotein retention as the initiating process in
atherosclerosis: update and therapeutic implications. Circ 2007;116:183244.
http://dx.doi.org/10.1161/CIRCULATIONAHA.106.676890
5. Calandra S, Tarugi P, Speedy HE, Dean AF, Bertolini S, Shoulders CC. Mechanisms and genetic
determinants regulating sterol absorption, circulating LDL levels, and sterol elimination:
implications for classification and disease risk. J Lipid Res 2011;52:1885926.
http://dx.doi.org/10.1194/jlr.R017855